A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
Giuseppe Curigliano, Geoffrey I. Shapiro, Rebecca Kristeleit, Albiruni R. Abdul Razak, Stephen Leong, María Alsina, Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark R. Middleton, Anthony J. Olszanski, Hope S. Rugo, Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka, Zev A. Wainberg
Topics & Concepts
TolerabilityMedicineMucositisDocetaxelInternal medicineResponse Evaluation Criteria in Solid TumorsBreast cancerTriple-negative breast cancerOncologyCancerPhases of clinical researchAdverse effectGastroenterologyChemotherapySurgeryPI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies